PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer

Abstract

Novel radiopharmaceuticals for PET are being evaluated for the diagnosis of biochemical recurrence (BCR) of prostate cancer (PC). We compared the gastrin-releasing peptide receptor-targeting ⁶⁸Ga-RM2 with the prostate-specific membrane antigen (PSMA)-targeting ⁶⁸Ga-PSMA11 and ¹⁸F-DCFPyL. <b>Methods:</b> Fifty patients underwent both ⁶⁸Ga-RM2 PET/MRI and ⁶⁸Ga-PSMA11 (<i>n</i> = 23) or ¹⁸F-DCFPyL (<i>n</i> = 27) PET/CT at an interval ranging from 1 to 60 d (mean ± SD, 15.8 ± 17.7 d). SUV_max was collected for all lesions. <b>Results:</b>⁶⁸Ga-RM2 PET was positive in 35 and negative in 15 of the 50 patients. ⁶⁸Ga-PSMA11/¹⁸F-DCFPyL PET was positive in 37 and negative in 13 of the 50 patients. Both scans detected 70 lesions in 32 patients. Forty-three lesions in 18 patients were identified on only 1 scan: ⁶⁸Ga-RM2 detected 7 more lesions in 4 patients, whereas ⁶⁸Ga-PSMA11/¹⁸F-DCFPyL detected 36 more lesions in 13 patients. <b>Conclusion:</b>⁶⁸Ga-RM2 remains a valuable radiopharmaceutical even when compared with the more widely used ⁶⁸Ga-PSMA11/¹⁸F-DCFPyL in the evaluation of BCR of PC. Larger studies are needed to verify that identifying patients for whom these 2 classes of radiopharmaceuticals are complementary may ultimately allow for personalized medicine.